Mr. Víctor Grífols Deu is Grifols' joint and several Chief Executive Officer together with Raimon Grífols Roura since 1 January 2017. He succeeds his father Victor Grífols Roura on the position. He is a member of the administration bodies of several companies within the Grifols Group and was appointed executive director in May 2016. He joined the Company in 2001 as an analyst in the Planning and Control Department of the Company. In 2008 he became the director of the Planning and Control Department and was also appointed member of the Executive Committees. He has been part of the team that analysed and was responsible for the integration of the operations after the acquisition of Alpha Therapeutics, Talecris Biotherapeutics and Novartis' Transfusion Diagnostic Unit. He graduated in Business Administration and Management from the Ramon Llull University – Sarrià Chemical Institute and holds a postgraduate degree in Business Administration and Management from Michael Smurfit Business School in Dublin. Relation with significant shareholders: Víctor Grífols Deu is the grandson of Nuria Roura Carreras (Rodellar Amsterdam Holdings B.V.).

 Clinical Sciences